163 related articles for article (PubMed ID: 22709589)
1. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice.
Mueller M; Reichardt W; Koerner J; Groettrup M
J Control Release; 2012 Aug; 162(1):159-66. PubMed ID: 22709589
[TBL] [Abstract][Full Text] [Related]
2. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy.
Schliehe C; Schliehe C; Thiry M; Tromsdorf UI; Hentschel J; Weller H; Groettrup M
J Control Release; 2011 May; 151(3):278-85. PubMed ID: 21223984
[TBL] [Abstract][Full Text] [Related]
3. Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.
Mueller M; Schlosser E; Gander B; Groettrup M
Int J Cancer; 2011 Jul; 129(2):407-16. PubMed ID: 21207410
[TBL] [Abstract][Full Text] [Related]
4. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response.
Fischer S; Schlosser E; Mueller M; Csaba N; Merkle HP; Groettrup M; Gander B
J Drug Target; 2009 Sep; 17(8):652-61. PubMed ID: 19622019
[TBL] [Abstract][Full Text] [Related]
5. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
6. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
7. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.
Schlosser E; Mueller M; Fischer S; Basta S; Busch DH; Gander B; Groettrup M
Vaccine; 2008 Mar; 26(13):1626-37. PubMed ID: 18295941
[TBL] [Abstract][Full Text] [Related]
8. Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells.
Waeckerle-Men Y; Allmen EU; Gander B; Scandella E; Schlosser E; Schmidtke G; Merkle HP; Groettrup M
Vaccine; 2006 Mar; 24(11):1847-57. PubMed ID: 16288821
[TBL] [Abstract][Full Text] [Related]
9. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery.
Zhang Z; Tongchusak S; Mizukami Y; Kang YJ; Ioji T; Touma M; Reinhold B; Keskin DB; Reinherz EL; Sasada T
Biomaterials; 2011 May; 32(14):3666-78. PubMed ID: 21345488
[TBL] [Abstract][Full Text] [Related]
10. Encapsulation of antigen in poly(D,L-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice.
Mohanan D; Gander B; Kündig TM; Johansen P
Eur J Pharm Biopharm; 2012 Feb; 80(2):274-81. PubMed ID: 22024408
[TBL] [Abstract][Full Text] [Related]
11. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
[TBL] [Abstract][Full Text] [Related]
12. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
13. The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.
Herrmann VL; Wieland DE; Legler DF; Wittmann V; Groettrup M
Prostate; 2016 Apr; 76(5):456-68. PubMed ID: 26715028
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice.
Luzardo-Alvarez A; Blarer N; Peter K; Romero JF; Reymond C; Corradin G; Gander B
J Control Release; 2005 Dec; 109(1-3):62-76. PubMed ID: 16269200
[TBL] [Abstract][Full Text] [Related]
15. Poly(d,l)-lactide-co-glycolide (PLGA) microspheres as immunoadjuvant for Brugia malayi antigens.
Saini V; Verma SK; Murthy PK; Kohli D
Vaccine; 2013 Aug; 31(38):4183-91. PubMed ID: 23827312
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.
Makkouk A; Joshi VB; Wongrakpanich A; Lemke CD; Gross BP; Salem AK; Weiner GJ
AAPS J; 2015 Jan; 17(1):184-93. PubMed ID: 25331103
[TBL] [Abstract][Full Text] [Related]
17. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
19. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines.
Waeckerle-Men Y; Groettrup M
Adv Drug Deliv Rev; 2005 Jan; 57(3):475-82. PubMed ID: 15560953
[TBL] [Abstract][Full Text] [Related]
20. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
San Román B; Gómez S; Irache JM; Espuelas S
J Pharm Pharm Sci; 2014; 17(4):541-53. PubMed ID: 25579433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]